EP1287822A3 - Mesalazine controlled release oral pharmaceutical compositions - Google Patents

Mesalazine controlled release oral pharmaceutical compositions Download PDF

Info

Publication number
EP1287822A3
EP1287822A3 EP02026576A EP02026576A EP1287822A3 EP 1287822 A3 EP1287822 A3 EP 1287822A3 EP 02026576 A EP02026576 A EP 02026576A EP 02026576 A EP02026576 A EP 02026576A EP 1287822 A3 EP1287822 A3 EP 1287822A3
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical compositions
oral pharmaceutical
release oral
controlled release
mesalazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP02026576A
Other languages
German (de)
French (fr)
Other versions
EP1287822A2 (en
EP1287822B1 (en
Inventor
Roberto Villa
Massimo Pedrani
Mauro Ajani
Lorenzo Fossati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cosmo Technologies Ltd
Original Assignee
Cosmo SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11383159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1287822(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cosmo SpA filed Critical Cosmo SpA
Publication of EP1287822A2 publication Critical patent/EP1287822A2/en
Publication of EP1287822A3 publication Critical patent/EP1287822A3/en
Application granted granted Critical
Publication of EP1287822B1 publication Critical patent/EP1287822B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

Controlled-release oral pharmaceutical compositions containing as active ingredient 5-amino-salicylic acid, comprising:
  • a) an inner lipophilic matrix consisting of substances with melting point below 90°C in which the active ingredient is at least partly inglobated;
  • b) an outer hydrophilic matrix in which the lipophilic matrix is dispersed;
  • c) optionally other excipients.
    •
    EP02026576A 1999-06-14 2000-06-08 Mesalazine controlled release oral pharmaceutical compositions Expired - Lifetime EP1287822B1 (en)

    Applications Claiming Priority (3)

    Application Number Priority Date Filing Date Title
    IT1999MI001316A ITMI991316A1 (en) 1999-06-14 1999-06-14 ORAL PHARMACEUTICAL COMPOSITIONS WITH MODIFIED RELEASE OF MESALAZINE
    ITMI991316 1999-06-14
    EP00935194A EP1198226B1 (en) 1999-06-14 2000-06-08 Mesalazine controlled release oral pharmaceutical compositions

    Related Parent Applications (2)

    Application Number Title Priority Date Filing Date
    EP00935194A Division EP1198226B1 (en) 1999-06-14 2000-06-08 Mesalazine controlled release oral pharmaceutical compositions
    EP00935194.1 Division 2000-06-08

    Publications (3)

    Publication Number Publication Date
    EP1287822A2 EP1287822A2 (en) 2003-03-05
    EP1287822A3 true EP1287822A3 (en) 2003-03-19
    EP1287822B1 EP1287822B1 (en) 2006-04-26

    Family

    ID=11383159

    Family Applications (2)

    Application Number Title Priority Date Filing Date
    EP02026576A Expired - Lifetime EP1287822B1 (en) 1999-06-14 2000-06-08 Mesalazine controlled release oral pharmaceutical compositions
    EP00935194A Expired - Lifetime EP1198226B1 (en) 1999-06-14 2000-06-08 Mesalazine controlled release oral pharmaceutical compositions

    Family Applications After (1)

    Application Number Title Priority Date Filing Date
    EP00935194A Expired - Lifetime EP1198226B1 (en) 1999-06-14 2000-06-08 Mesalazine controlled release oral pharmaceutical compositions

    Country Status (18)

    Country Link
    US (1) US6773720B1 (en)
    EP (2) EP1287822B1 (en)
    JP (2) JP4727875B2 (en)
    CN (2) CN100448448C (en)
    AT (2) ATE235234T1 (en)
    AU (1) AU5077200A (en)
    CA (1) CA2377299C (en)
    DE (2) DE60001835T2 (en)
    DK (2) DK1287822T3 (en)
    ES (2) ES2194732T3 (en)
    HK (2) HK1046247B (en)
    IT (1) ITMI991316A1 (en)
    MX (1) MXPA01012888A (en)
    NO (1) NO329402B1 (en)
    PT (2) PT1198226E (en)
    RU (1) RU2245148C2 (en)
    TR (1) TR200200561T2 (en)
    WO (1) WO2000076481A1 (en)

    Families Citing this family (53)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    US8895064B2 (en) 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
    AU5680100A (en) 1999-06-14 2001-01-02 Cosmo S.P.A. Controlled release and taste masking oral pharmaceutical compositions
    CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
    US8282955B2 (en) 2001-10-15 2012-10-09 Ferring B.V. Method for the preparation of a pharmaceutical composition comprising 5-aminosalicylic acid for use in treatment of ulcerative colitis and Crohn's disease
    ITMI20012599A1 (en) * 2001-12-11 2003-06-11 Cosmo Spa PHARMACEUTICAL COMPOSITIONS FOR THE ORAL ADMINISTRATION OF HEPARINE OR DERIVATIVES, USEFUL FOR THERAPY OF INFLAMMATORY DISEASES OF THE INT
    US9308220B2 (en) 2001-12-11 2016-04-12 Cosmo Technologies Limited Pharmaceutical compositions for the oral administration of heparin or derivatives thereof
    US20030118329A1 (en) * 2001-12-21 2003-06-26 Pere Obrador Video indexing using high resolution still images
    KR100540035B1 (en) * 2002-02-01 2005-12-29 주식회사 태평양 Multi-stage oral drug controlled-release system
    FR2852843B1 (en) 2003-03-24 2008-05-23 Karim Ioualalen GALENIC SYSTEM FOR MASKING TASTE
    CA2520197A1 (en) * 2003-04-23 2004-11-04 Ferring B.V. Sachet for a pharmaceutical composition
    US7825106B2 (en) * 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
    US7737133B2 (en) 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
    GB0322848D0 (en) * 2003-09-30 2003-10-29 Alpharma Ltd Tetracycline controlled release pharmaceutical dosage form
    US20050152974A1 (en) * 2003-12-31 2005-07-14 Garth Boehm Atomoxetine formulations
    US7417037B2 (en) 2004-01-20 2008-08-26 The Board Of Regents Of The University Of Oklahoma Compositions and methods of treatment for inflammatory diseases
    US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
    US7700651B2 (en) 2006-07-19 2010-04-20 The Board Of Regents Of The University Of Texas System Preparations of phospholipids and pharmaceuticals containing 5-amino salicylic acid for the treatment of inflammatory bowel disease
    MX2009002785A (en) * 2006-09-13 2009-03-30 Procter & Gamble Methods of treatment for ulcerative colitis.
    CA2662430A1 (en) * 2006-09-13 2008-03-20 The Procter & Gamble Company Methods of treatment for ulcerative colitis using aminosalicylate
    AU2007321906A1 (en) 2006-11-17 2008-05-29 Shire Development Inc. Method of treatment for inflammatory bowel disease
    FR2913884A1 (en) * 2007-03-21 2008-09-26 Oralance Pharma Sa NON-IONIZABLE HYDROPHOBIC GALENIC SYSTEM
    US20090028944A1 (en) * 2007-07-16 2009-01-29 Balaji Sathurappan Pharmaceutical compositions comprising mesalamine
    US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
    US20090169622A1 (en) * 2007-12-27 2009-07-02 Roxane Laboratories, Inc. Delayed-release oral pharmaceutical composition for treatment of colonic disorders
    US20110097401A1 (en) 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
    WO2011045775A1 (en) * 2009-10-16 2011-04-21 Ranbaxy Laboratories Limited A delayed release pharmaceutical composition of mesalamine
    IT1398643B1 (en) 2010-03-04 2013-03-08 Cosmo Technologies Ltd SOLID COMPOSITION FOR ORAL ADMINISTRATION OF DYES, AND DIAGNOSTIC USE OF THE SAME
    EP2425826A1 (en) * 2010-09-01 2012-03-07 Disphar International B.V. Mesalazine tablet having improved dissolution
    IT1402047B1 (en) * 2010-10-19 2013-08-28 Cross Pharma Sa USE OF MEXIPROSTIL IN THE TREATMENT OF INTESTINAL INFLAMMATORY DISEASES
    EP2468264A1 (en) 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
    DK2661266T3 (en) 2011-01-07 2020-11-16 Anji Pharma Us Llc CHEMOSENSORIC RECEPTOR LIGAND BASED THERAPIES
    US9795792B2 (en) 2011-02-25 2017-10-24 Medtronic, Inc. Emergency mode switching for non-pacing modes
    US10154964B2 (en) 2011-09-07 2018-12-18 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
    AU2012363873B2 (en) 2012-01-06 2017-11-23 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
    EA033067B1 (en) 2012-01-06 2019-08-30 Элселикс Терапьютикс, Инк. Method for treating metabolic disorders in a patient having a contraindication for a biguanide compound
    WO2013134348A1 (en) * 2012-03-07 2013-09-12 Santarus, Inc. Controlled-release solid dosage forms of mesalamine
    WO2013144176A1 (en) 2012-03-30 2013-10-03 Laboratorios Del Dr. Esteve, S.A. Controlled release formulatin comprising mesalamine
    WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
    JP2015522080A (en) 2012-07-11 2015-08-03 エルセリクス セラピューティクス インコーポレイテッド Compositions for reducing cardiovascular metabolic risk comprising statins, biguanides, and additional agents
    EP2722058A1 (en) 2012-10-19 2014-04-23 Cosmo Technologies Ltd Solid oral composition containing dyes for use in endoscopic diagnosis
    EP2941245A1 (en) 2013-01-05 2015-11-11 Elcelyx Therapeutics, Inc. Delayed-release composition comprising biguanide
    TWI688411B (en) * 2013-02-22 2020-03-21 日商志瑞亞新藥工業股份有限公司 Enteric-coated tablets
    EP2953619A1 (en) 2013-03-15 2015-12-16 Warner Chilcott Company, LLC Mesalamine pharmaceutical composition with multiple dosage elements for reduced delivery variability
    US9539265B2 (en) 2013-03-15 2017-01-10 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
    CN104922090B (en) * 2015-07-03 2017-11-14 湖南方盛制药股份有限公司 Mesalazine enteric sustained-release pellet
    EP3162362A1 (en) 2015-10-30 2017-05-03 Dr. Falk Pharma Gmbh Optimized high-dose tablet of mesalazine
    ITUA20162293A1 (en) 2016-04-05 2017-10-05 Sofar Spa Process for solid formulations of mesalazine
    US20200061212A1 (en) 2016-11-28 2020-02-27 Cosmo Technologies Ltd. Solid oral composition containing dyes
    US10098898B1 (en) 2017-12-04 2018-10-16 Handa Pharmaceuticals, Llc Release stable mesalamine dosage forms
    EP3501503A1 (en) * 2017-12-22 2019-06-26 Cosmo Technologies Ltd. Solid delivery composition
    EP3662895A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG A process for manufacturing reducing sugar-free 5-asa tablet cores
    IT201800011120A1 (en) 2018-12-14 2020-06-14 Dpl Pharma S P A SOLID ORAL PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF MESALAZINE OR ITS DERIVATIVES
    CN112587506A (en) * 2020-12-09 2021-04-02 南京森博医药研发有限公司 Method for preparing mesalazine enteric sustained-release capsule

    Citations (5)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    GB2245492A (en) * 1990-07-04 1992-01-08 Zambon Spa Programmed release oral solid pharmaceutical dosage form
    US5593690A (en) * 1988-11-08 1997-01-14 Takeda Chemical Industries, Ltd. Sustained release preparations
    WO1998026767A2 (en) * 1996-12-17 1998-06-25 Poli Industria Chimica S.P.A. Site-specific controlled release dosage formulation for mesalamine
    US5851555A (en) * 1997-08-15 1998-12-22 Fuisz Technologies Ltd. Controlled release dosage forms containing water soluble drugs
    WO2000076478A1 (en) * 1999-06-14 2000-12-21 Cosmo S.P.A. Controlled release and taste masking oral pharmaceutical compositions

    Family Cites Families (12)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    US4921757A (en) * 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
    JPS6248618A (en) * 1985-08-27 1987-03-03 Zeria Shinyaku Kogyo Kk Slow-releasing drug preparation and production thereof
    IL92343A0 (en) * 1988-12-20 1990-07-26 Gist Brocades Nv Granulate for multiparticulate controlled release oral compositions,their preparation and oral pharmaceutical compositions containing them
    IL92344A0 (en) * 1989-01-04 1990-07-26 Gist Brocades Nv Microencapsulation of bioactive substances in biocompatible polymers,microcapsules obtained and pharmaceutical preparation comprising said microcapsules
    JPH02282323A (en) * 1989-04-21 1990-11-19 Shin Etsu Chem Co Ltd Production of sustained release tablet
    JPH03232814A (en) * 1990-02-08 1991-10-16 Shin Etsu Chem Co Ltd Production of sustained release tablet
    JP3011752B2 (en) * 1990-10-23 2000-02-21 フロイント産業株式会社 Sustained-release preparation and method for producing the same
    JP2829794B2 (en) * 1991-02-08 1998-12-02 エスエス製薬 株式会社 Orally administered pranoprofen formulation for sustained release
    GEP19971086B (en) * 1991-02-22 1997-12-02 Tillotts Pharma Ag Peroral Pharmaceutically Dispensed Form for Selective Introducing of the Medicine into the Intestine
    JPH0624962A (en) * 1992-07-09 1994-02-01 Green Cross Corp:The Enteric sustained release solid pharmaceutical preparation
    ATE223704T1 (en) * 1992-10-16 2002-09-15 Nippon Shinyaku Co Ltd METHOD FOR PRODUCING WAX MATRICES
    US5911980A (en) * 1996-06-27 1999-06-15 Macrochem Corporation Lipophilic and amphiphilic or hydrophilic film-forming polymer compositions, and use thereof in topical agent delivery system and method of delivering agents to the skin

    Patent Citations (5)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    US5593690A (en) * 1988-11-08 1997-01-14 Takeda Chemical Industries, Ltd. Sustained release preparations
    GB2245492A (en) * 1990-07-04 1992-01-08 Zambon Spa Programmed release oral solid pharmaceutical dosage form
    WO1998026767A2 (en) * 1996-12-17 1998-06-25 Poli Industria Chimica S.P.A. Site-specific controlled release dosage formulation for mesalamine
    US5851555A (en) * 1997-08-15 1998-12-22 Fuisz Technologies Ltd. Controlled release dosage forms containing water soluble drugs
    WO2000076478A1 (en) * 1999-06-14 2000-12-21 Cosmo S.P.A. Controlled release and taste masking oral pharmaceutical compositions

    Also Published As

    Publication number Publication date
    ATE235234T1 (en) 2003-04-15
    NO20016107D0 (en) 2001-12-14
    JP2003501458A (en) 2003-01-14
    JP5235839B2 (en) 2013-07-10
    WO2000076481A1 (en) 2000-12-21
    EP1287822A2 (en) 2003-03-05
    HK1085669A1 (en) 2006-09-01
    DE60001835D1 (en) 2003-04-30
    DE60027608T2 (en) 2007-04-26
    JP2010024241A (en) 2010-02-04
    PT1198226E (en) 2003-07-31
    EP1287822B1 (en) 2006-04-26
    DE60027608D1 (en) 2006-06-01
    NO20016107L (en) 2002-02-11
    ES2194732T3 (en) 2003-12-01
    HK1046247A1 (en) 2003-01-03
    NO329402B1 (en) 2010-10-11
    CN1355694A (en) 2002-06-26
    US6773720B1 (en) 2004-08-10
    CN1217665C (en) 2005-09-07
    EP1198226B1 (en) 2003-03-26
    PT1287822E (en) 2006-07-31
    HK1046247B (en) 2006-04-07
    EP1198226A1 (en) 2002-04-24
    MXPA01012888A (en) 2002-07-30
    JP4727875B2 (en) 2011-07-20
    ATE324104T1 (en) 2006-05-15
    CN100448448C (en) 2009-01-07
    CA2377299A1 (en) 2000-12-21
    ITMI991316A1 (en) 2000-12-14
    CA2377299C (en) 2009-05-12
    DK1198226T3 (en) 2003-07-21
    ES2262749T3 (en) 2006-12-01
    AU5077200A (en) 2001-01-02
    CN1720919A (en) 2006-01-18
    ITMI991316A0 (en) 1999-06-14
    DE60001835T2 (en) 2003-11-13
    TR200200561T2 (en) 2002-06-21
    RU2245148C2 (en) 2005-01-27
    DK1287822T3 (en) 2006-08-28

    Similar Documents

    Publication Publication Date Title
    EP1287822A3 (en) Mesalazine controlled release oral pharmaceutical compositions
    EP2322146A3 (en) Microcapsule formulations comprising two pharmaceutically active ingredients
    CA2307018A1 (en) Osmotic medicament releasing system
    CA2385890A1 (en) Controlled release compositions comprising nimesulide
    IE871584L (en) Sustained release capsule.
    BRPI0015567B8 (en) compound, pharmaceutical composition, dosage unit form, use of the pharmaceutical composition and method for preparing a pharmaceutical composition
    CA2123160A1 (en) Controlled release formulation
    WO2000041681A3 (en) MEDICINAL FORMULATIONS CONTAINING AN OPIOID AND AN α-ANTAGONIST
    AU1351788A (en) Slow-release pharmaceutical agent
    ZA200000169B (en) Process for the preparation of pellets with a content of up to 90 wt.% of a pharmaceutical active ingredient.
    CA2339913A1 (en) Pharmaceutical formulations and method for making
    AU2001278772A1 (en) Benzoic acid derivatives and drugs containing the same as the active ingredient
    AU2001234107A1 (en) Benzoic acid derivatives, process for producing the same and drugs containing the same as the active ingredient
    AU3669700A (en) 4-aminobutanoic acid derivatives and drugs containing these derivatives as the active ingredient
    WO2003041656A3 (en) Soluble drug extended release system
    CA2362769A1 (en) Microcapsules for sustained release of drugs
    AU2002363776A1 (en) Carboxylic acid derivative compounds and drugs containing the same as the active ingredient
    WO2001070205A3 (en) Composition comprising paracetamol and niflumic acid
    ITMI20000972A0 (en) PHARMACEUTICAL FORMULATIONS, WITH MODIFIED RELEASE, WITH HIGH BIOAVAILABILITY, CONTAINING ACTIVE INGREDIENTS WITH ANTIBIOTIC ACTIVITY.
    AU2002323916A1 (en) Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
    AU2002225349B2 (en) Dihydronaphthalene derivative compounds and drugs containing these compounds as the active ingredient
    AU2002355691A1 (en) Pharmaceutical preparations containing aminobenzene- sulfonic acid derivatives as the active ingredient
    IT1317871B1 (en) Controlled release and taste masking oral compositions comprising active ingredient incorporated in a matrix structure
    AU2002225349A1 (en) Dihydronaphthalene derivative compounds and drugs containing these compounds as the active ingredient

    Legal Events

    Date Code Title Description
    PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

    Free format text: ORIGINAL CODE: 0009012

    PUAL Search report despatched

    Free format text: ORIGINAL CODE: 0009013

    AC Divisional application: reference to earlier application

    Ref document number: 1198226

    Country of ref document: EP

    Kind code of ref document: P

    AK Designated contracting states

    Kind code of ref document: A2

    Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

    AK Designated contracting states

    Kind code of ref document: A3

    Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

    17P Request for examination filed

    Effective date: 20030902

    AKX Designation fees paid

    Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

    17Q First examination report despatched

    Effective date: 20050523

    GRAP Despatch of communication of intention to grant a patent

    Free format text: ORIGINAL CODE: EPIDOSNIGR1

    RAP1 Party data changed (applicant data changed or rights of an application transferred)

    Owner name: COSMO TECHNOLOGIES LTD

    GRAS Grant fee paid

    Free format text: ORIGINAL CODE: EPIDOSNIGR3

    GRAA (expected) grant

    Free format text: ORIGINAL CODE: 0009210

    AC Divisional application: reference to earlier application

    Ref document number: 1198226

    Country of ref document: EP

    Kind code of ref document: P

    AK Designated contracting states

    Kind code of ref document: B1

    Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

    REG Reference to a national code

    Ref country code: GB

    Ref legal event code: FG4D

    REG Reference to a national code

    Ref country code: IE

    Ref legal event code: FG4D

    REF Corresponds to:

    Ref document number: 60027608

    Country of ref document: DE

    Date of ref document: 20060601

    Kind code of ref document: P

    REG Reference to a national code

    Ref country code: CH

    Ref legal event code: NV

    Representative=s name: ISLER & PEDRAZZINI AG

    Ref country code: PT

    Ref legal event code: SC4A

    Effective date: 20060608

    REG Reference to a national code

    Ref country code: GR

    Ref legal event code: EP

    Ref document number: 20060401930

    Country of ref document: GR

    REG Reference to a national code

    Ref country code: SE

    Ref legal event code: TRGR

    REG Reference to a national code

    Ref country code: DK

    Ref legal event code: T3

    REG Reference to a national code

    Ref country code: ES

    Ref legal event code: FG2A

    Ref document number: 2262749

    Country of ref document: ES

    Kind code of ref document: T3

    ET Fr: translation filed
    PLBE No opposition filed within time limit

    Free format text: ORIGINAL CODE: 0009261

    STAA Information on the status of an ep patent application or granted ep patent

    Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

    26N No opposition filed

    Effective date: 20070129

    REG Reference to a national code

    Ref country code: CH

    Ref legal event code: PCAR

    Free format text: ISLER & PEDRAZZINI AG;POSTFACH 1772;8027 ZUERICH (CH)

    REG Reference to a national code

    Ref country code: FR

    Ref legal event code: PLFP

    Year of fee payment: 17

    REG Reference to a national code

    Ref country code: FR

    Ref legal event code: PLFP

    Year of fee payment: 18

    REG Reference to a national code

    Ref country code: FR

    Ref legal event code: PLFP

    Year of fee payment: 19

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: MC

    Payment date: 20190624

    Year of fee payment: 20

    Ref country code: IT

    Payment date: 20190619

    Year of fee payment: 20

    Ref country code: CY

    Payment date: 20190529

    Year of fee payment: 20

    Ref country code: FI

    Payment date: 20190618

    Year of fee payment: 20

    Ref country code: NL

    Payment date: 20190619

    Year of fee payment: 20

    Ref country code: PT

    Payment date: 20190530

    Year of fee payment: 20

    Ref country code: DK

    Payment date: 20190624

    Year of fee payment: 20

    Ref country code: LU

    Payment date: 20190619

    Year of fee payment: 20

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: GR

    Payment date: 20190619

    Year of fee payment: 20

    Ref country code: BE

    Payment date: 20190619

    Year of fee payment: 20

    Ref country code: FR

    Payment date: 20190626

    Year of fee payment: 20

    Ref country code: SE

    Payment date: 20190624

    Year of fee payment: 20

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: CH

    Payment date: 20190624

    Year of fee payment: 20

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: AT

    Payment date: 20190618

    Year of fee payment: 20

    Ref country code: GB

    Payment date: 20190617

    Year of fee payment: 20

    Ref country code: DE

    Payment date: 20190624

    Year of fee payment: 20

    Ref country code: IE

    Payment date: 20190722

    Year of fee payment: 20

    Ref country code: ES

    Payment date: 20190723

    Year of fee payment: 20

    REG Reference to a national code

    Ref country code: DE

    Ref legal event code: R071

    Ref document number: 60027608

    Country of ref document: DE

    REG Reference to a national code

    Ref country code: NL

    Ref legal event code: MK

    Effective date: 20200607

    REG Reference to a national code

    Ref country code: DK

    Ref legal event code: EUP

    Expiry date: 20200608

    Ref country code: CH

    Ref legal event code: PL

    REG Reference to a national code

    Ref country code: GB

    Ref legal event code: PE20

    Expiry date: 20200607

    REG Reference to a national code

    Ref country code: FI

    Ref legal event code: MAE

    REG Reference to a national code

    Ref country code: IE

    Ref legal event code: MK9A

    REG Reference to a national code

    Ref country code: SE

    Ref legal event code: EUG

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: PT

    Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

    Effective date: 20200618

    REG Reference to a national code

    Ref country code: AT

    Ref legal event code: MK07

    Ref document number: 324104

    Country of ref document: AT

    Kind code of ref document: T

    Effective date: 20200608

    REG Reference to a national code

    Ref country code: BE

    Ref legal event code: MK

    Effective date: 20200608

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: GB

    Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

    Effective date: 20200607

    REG Reference to a national code

    Ref country code: ES

    Ref legal event code: FD2A

    Effective date: 20200925

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: ES

    Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

    Effective date: 20200609

    Ref country code: IE

    Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

    Effective date: 20200608